Previous meta-analyses have focused mainly on the effects of SGLT2 inhibitors on heart failure or HFrEF, but there was no HFpEF-specific meta-analysis, or only described that in the subgroup analysis. The gene discussed is SLC5A2; the disease is heart failure.